These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 32407439)

  • 21. Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers.
    Eso Y; Shimizu T; Takeda H; Takai A; Marusawa H
    J Gastroenterol; 2020 Jan; 55(1):15-26. PubMed ID: 31494725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Clinic Experience.
    Coston T; Desai A; Babiker H; Sonbol MB; Chakrabarti S; Mahipal A; McWilliams R; Ma WW; Bekaii-Saab TS; Stauffer J; Starr JS
    JCO Precis Oncol; 2023 Aug; 7():e2200706. PubMed ID: 37625102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood Tumor Mutational Burden Alone Is Not a Good Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Gastrointestinal Tumors.
    Yu J; Park R; Miao R; Imanirad I; Shahzad M; Laborde JM; Knepper TC; Walko CM; Kim R
    J Immunother; 2024 Nov-Dec 01; 47(9):378-383. PubMed ID: 39012081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study.
    Guven DC; Aykan MB; Muglu H; Bayram E; Helvaci K; Dursun B; Celayir M; Chelebiyev E; Nayir E; Erman M; Sezer A; Urun Y; Demirci U; Er O; Disel U; Bilici A; Arslan C; Karadurmus N; Kilickap S
    Cancer Med; 2024 Jan; 13(1):e6869. PubMed ID: 38140782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies.
    Zhang L; Feng J; Kuang T; Chai D; Qiu Z; Deng W; Dong K; Zhao K; Wang W
    Int Immunopharmacol; 2023 May; 118():110019. PubMed ID: 36933492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
    Colle R; Radzik A; Cohen R; Pellat A; Lopez-Tabada D; Cachanado M; Duval A; Svrcek M; Menu Y; André T
    Eur J Cancer; 2021 Feb; 144():9-16. PubMed ID: 33316636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers.
    Fucà G; Cohen R; Lonardi S; Shitara K; Elez ME; Fakih M; Chao J; Klempner SJ; Emmett M; Jayachandran P; Bergamo F; García MD; Mazzoli G; Provenzano L; Colle R; Svrcek M; Ambrosini M; Randon G; Shah AT; Salati M; Fenocchio E; Salvatore L; Chida K; Kawazoe A; Conca V; Curigliano G; Corti F; Cremolini C; Overman M; Andre T; Pietrantonio F
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant Immune Checkpoint Inhibitor Therapy for Patients With Microsatellite Instability-High Colorectal Cancer: Shedding Light on the Future.
    Sahin IH; Zhang J; Saridogan T; Gorantla V; Rhree J; Malhotra M; Thomas R; Hsu D; Saeed A
    JCO Oncol Pract; 2023 May; 19(5):251-259. PubMed ID: 36862965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Xie E; Yeo YH; Scheiner B; Zhang Y; Hiraoka A; Tantai X; Fessas P; de Castro T; D'Alessio A; Fulgenzi CAM; Xu S; Tsai HM; Kambhampati S; Wang W; Keenan BP; Gao X; Xing Z; Pinter M; Lin YJ; Guo Z; Vogel A; Tanaka T; Kuo HY; Kelley RK; Kudo M; Yang JD; Pinato DJ; Ji F
    JAMA Oncol; 2023 Oct; 9(10):1423-1431. PubMed ID: 37615958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.
    Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L
    Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic relevance of prognostic nutritional indices in gastric or gastro-esophageal junction cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
    Hou S; Song D; Hao R; Li L; Zhang Y; Zhu J
    Front Immunol; 2024; 15():1382417. PubMed ID: 38966640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis.
    Xu H; Cao D; Zheng Y; Zhou D; Chen X; Lei J; Ge W; Xu X
    Int Immunopharmacol; 2021 Nov; 100():108135. PubMed ID: 34530205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis.
    Wu Y; Xu J; Du C; Wu Y; Xia D; Lv W; Hu J
    Front Oncol; 2019; 9():1161. PubMed ID: 31750249
    [No Abstract]   [Full Text] [Related]  

  • 35. Performance of Low-Dose Immunotherapy and Standard-Dose Immunotherapy in Microsatellite Instability-High Metastatic Colorectal Cancer: Real-World Data (CLouD-High Study).
    Trikha M; Sarkar L; Dhanawat A; Syed N; Gujarathi H; Vora M; Sivakumar Raja AS; Bhargava P; Ramaswamy A; Mandavkar S; Saklani A; Kaushal RK; Bal M; Shetty O; Yadav S; Ostwal V
    JCO Glob Oncol; 2024 Aug; 10():e2400141. PubMed ID: 39159410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
    Kim H; Kim DW; Kim M; Lee Y; Ahn HK; Cho JH; Kim IH; Lee YG; Shin SH; Park SE; Jung J; Kang EJ; Ahn MJ
    Cancer; 2022 Feb; 128(4):778-787. PubMed ID: 34705268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy in MMR-d/MSI-H recurrent/metastatic endometrial cancer.
    Pacholczak-Madej R; Bartoletti M; Musacchio L; Püsküllüoglu M; Blecharz P; Lorusso D
    Expert Rev Anticancer Ther; 2024 Aug; 24(8):717-729. PubMed ID: 38863432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors.
    Li J; Deng Y; Zhang W; Zhou AP; Guo W; Yang J; Yuan Y; Zhu L; Qin S; Xiang S; Lu H; Gong J; Xu T; Liu D; Shen L
    J Hematol Oncol; 2021 Jun; 14(1):95. PubMed ID: 34154614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-oncology Clinical Trials.
    Hu C; Wang M; Wu C; Zhou H; Chen C; Diede S
    JAMA Netw Open; 2021 May; 4(5):e218175. PubMed ID: 34047794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation.
    Cohen R; Raeisi M; Chibaudel B; Yoshino T; Shi Q; Zalcberg JR; Adams R; Cremolini C; Grothey A; Mayer RJ; Van Cutsem E; Tabernero J; Bando H; Misumi T; Overman MJ; André T; de Gramont A
    Eur J Cancer; 2024 Mar; 199():113537. PubMed ID: 38241818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.